Tirzepatide, a dual GIP and GLP-1 receptor agonist, is a promising treatment for type 2 diabetes mellitus (T2DM). We aim to assess the efficacy and safety of Tirzepatide compared to long-acting insulin in T2DM patients.
(2024). Tirzepatide Versus Long-Acting Insulin: A Systematic Review and Meta-Analysis. Egyptian Society of Diabetes and Lipidology Journal, 4(2), -. doi: 10.21608/esdlj.2024.456243
MLA
. "Tirzepatide Versus Long-Acting Insulin: A Systematic Review and Meta-Analysis", Egyptian Society of Diabetes and Lipidology Journal, 4, 2, 2024, -. doi: 10.21608/esdlj.2024.456243
HARVARD
(2024). 'Tirzepatide Versus Long-Acting Insulin: A Systematic Review and Meta-Analysis', Egyptian Society of Diabetes and Lipidology Journal, 4(2), pp. -. doi: 10.21608/esdlj.2024.456243
VANCOUVER
Tirzepatide Versus Long-Acting Insulin: A Systematic Review and Meta-Analysis. Egyptian Society of Diabetes and Lipidology Journal, 2024; 4(2): -. doi: 10.21608/esdlj.2024.456243
)
